JP2006515013A - グリコーゲン合成酵素キナーゼ３β活性抑制剤、組成物及びその製造方法 - Google Patents

グリコーゲン合成酵素キナーゼ３β活性抑制剤、組成物及びその製造方法 Download PDF

Info

Publication number
JP2006515013A
JP2006515013A JP2005518551A JP2005518551A JP2006515013A JP 2006515013 A JP2006515013 A JP 2006515013A JP 2005518551 A JP2005518551 A JP 2005518551A JP 2005518551 A JP2005518551 A JP 2005518551A JP 2006515013 A JP2006515013 A JP 2006515013A
Authority
JP
Japan
Prior art keywords
compound
alkyl
optionally substituted
mmol
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2005518551A
Other languages
English (en)
Japanese (ja)
Inventor
チョ、ジョン・ミュン
ロ、ソング
リ、テ・ギュ
リ、キュン・ジョ
シン、ドンキュ
ヒュン、ユン−ラン
リ、スン・チュル
キム、ジン・ホワン
ジョン、ユン・ホ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CrystalGenomics Inc
Yuyu Inc
Original Assignee
CrystalGenomics Inc
Yuyu Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CrystalGenomics Inc, Yuyu Inc filed Critical CrystalGenomics Inc
Publication of JP2006515013A publication Critical patent/JP2006515013A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2005518551A 2003-01-23 2004-01-20 グリコーゲン合成酵素キナーゼ３β活性抑制剤、組成物及びその製造方法 Ceased JP2006515013A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20030004608 2003-01-23
KR20030004607 2003-01-23
KR20030042442 2003-06-27
PCT/KR2004/000097 WO2004065370A1 (en) 2003-01-23 2004-01-20 Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof

Publications (1)

Publication Number Publication Date
JP2006515013A true JP2006515013A (ja) 2006-05-18

Family

ID=36146164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005518551A Ceased JP2006515013A (ja) 2003-01-23 2004-01-20 グリコーゲン合成酵素キナーゼ３β活性抑制剤、組成物及びその製造方法

Country Status (5)

Country Link
US (1) US7179832B2 (de)
EP (1) EP1590333A4 (de)
JP (1) JP2006515013A (de)
KR (1) KR100791252B1 (de)
WO (1) WO2004065370A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010058512A1 (en) * 2008-11-20 2010-05-27 Oncotherapy Science, Inc. Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
UY29823A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE602006013191D1 (de) 2005-11-15 2010-05-06 Abbott Lab Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
AU2006327243A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
US20090170847A1 (en) * 2006-01-23 2009-07-02 Seung Chul Lee Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2012780B1 (de) 2006-05-02 2012-04-11 Abbott Laboratories Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008059023A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc New haloalkylsulfone substituted compounds useful for treating obesity and diabetes
ES2377322T3 (es) 2006-11-15 2012-03-26 High Point Pharmaceuticals, Llc Nuevas 2-(2-hidroxifenil)benzotiadiazinas útiles para el tratamiento de la obesidad y la diabetes
WO2008059026A1 (en) * 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
EP2142542A4 (de) * 2007-03-30 2011-06-22 Astrazeneca Ab Neue imidazo[4,5-b]pyridin-7-carbonsäureamide 704
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
AU2009276548A1 (en) * 2008-07-30 2010-02-04 Oncotherapy Science, Inc. Benzoimidazole derivatives and glycogen synthase kinase-3 beta inhibitors containing the same
CN102271514A (zh) * 2008-10-30 2011-12-07 肿瘤疗法科学股份有限公司 7-羟基-苯并咪唑-4-基-甲酮衍生物以及包含其的pbk抑制剂
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011004405A1 (en) 2009-07-10 2011-01-13 Decode Genetics Ehf Genetic markers associated with risk of diabetes mellitus
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
DE102011106990B3 (de) * 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529773A (en) * 1982-03-17 1985-07-16 David Witiak Alkali-soluble emulsion polymers in acidic surfactant compositions
GB2245279B (en) * 1990-06-20 1993-04-07 Unilever Plc Shampoo composition
FR2676923B1 (fr) * 1991-06-03 1995-04-21 Oreal Composition de traitement des matieres keratiniques a base de silicone et de latex.
DE4330959A1 (de) 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5534265A (en) * 1994-08-26 1996-07-09 The Procter & Gamble Company Thickened nonabrasive personal cleansing compositions
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
NZ313713A (en) * 1995-08-02 2001-03-30 Univ Newcastle Ventures Ltd Benzimidazole-4-carboxamide derivatives useful as poly(ADP-ribose)polymerase or PARP enzyme inhibitors
PL347684A1 (en) * 1998-11-17 2002-04-22 Basf Ag 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
US20030096852A1 (en) * 2001-06-15 2003-05-22 Genentech, Inc. Human growth hormone antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010058512A1 (en) * 2008-11-20 2010-05-27 Oncotherapy Science, Inc. Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives

Also Published As

Publication number Publication date
WO2004065370A1 (en) 2004-08-05
EP1590333A1 (de) 2005-11-02
KR100791252B1 (ko) 2008-01-03
US20060079521A1 (en) 2006-04-13
KR20050109930A (ko) 2005-11-22
US7179832B2 (en) 2007-02-20
EP1590333A4 (de) 2008-04-30

Similar Documents

Publication Publication Date Title
JP2006515013A (ja) グリコーゲン合成酵素キナーゼ３β活性抑制剤、組成物及びその製造方法
JP7352662B2 (ja) ベンゾイソオキサゾールスルホンアミド誘導体
KR100815772B1 (ko) 신규 고리상 아미드 유도체
CA2816753A1 (en) N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
WO2000064894A1 (fr) Composes 5-pyridyle-1,3-azole, leur procede de fabrication et leur utilisation
WO2013019653A1 (en) Compounds and methods
WO2001081345A1 (fr) Composes d'amides aromatiques
JP2003532730A (ja) 細胞増殖抑制剤として有用な１，１−ジオキソイソチアゾリジンを持つインダゾール
WO2007063925A1 (ja) ２－アミノベンズアミド誘導体
JP5734532B2 (ja) アゾールベンゼン誘導体
JP2009542752A (ja) 置換イソオキサゾリン、それを含有する医薬組成物、それを調製する方法、及びその使用
WO2013019682A1 (en) Compounds and methods
KR20080072688A (ko) 옥사디아졸 유도체
KR101386679B1 (ko) 신규한 아릴피페라진-함유 이미다졸 4-카복사마이드 유도체 및 이를 포함하는 약학 조성물
EP1828177A2 (de) Neue mch-rezeptorantagonisten
JP6134072B2 (ja) キサンチンオキシダーゼ阻害薬
EP2611772A1 (de) 2 - (benzyloxy)-benzamide als lrrk2-kinasehemmer
EP2914591A1 (de) Inhibitoren des cytomegalovirus
IL269119B2 (en) Dual inhibitors of magl and faah
JP2011088847A (ja) 三環性化合物およびその用途
WO2017073743A1 (ja) 三環性化合物
US7166624B2 (en) Peptide deformylase inhibitors
WO1999061412A1 (fr) Derives d'acide hydroxamique et utilisation medicinale de ces derives
JPH05239065A (ja) 三環性複素環類、その製造法及び剤
CA3215443A1 (en) Substituted pyrrole carboxamides, process for their preparation and their use as kinase inhibitors

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090407

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091202

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091225

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100202

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20100622